Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly reduced prices following the expiration of Boehringer Ingelheims patent. Mankind ...

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic control and weight-loss in diabetes patients.

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

USV launches empagliflozin and its combinations for diabetes care in India: Our Bureau, Bengaluru Wednesday, March 19, 2025, 12:40 Hrs [IST] USV, an Indian multinational healthcar ...

Mankind Pharma has launched generic versions of diabetes medication Empagliflozin under brand names Empaglyde, Empagreat, and Dynaduo, offering affordable treatment options.

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...

Empagliflozin is indicated to improve glycemic control in adults with type 2 diabetes mellitus. (Image Credits: Pixabay) Boehringer Ingelheim’s blockbuster diabetes drug, Empagliflozin ...